BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014;88:1651-68. [DOI: 10.1007/s00204-014-1315-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Feng J, Meng X. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. Front Pharmacol 2022;13:946811. [DOI: 10.3389/fphar.2022.946811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ahmed YW, Alemu BA, Bekele SA, Gizaw ST, Zerihun MF, Wabalo EK, Teklemariam MD, Mihrete TK, Hanurry EY, Amogne TG, Gebrehiwot AD, Berga TN, Haile EA, Edo DO, Alemu BD. Epigenetic tumor heterogeneity in the era of single-cell profiling with nanopore sequencing. Clin Epigenetics 2022;14:107. [PMID: 36030244 DOI: 10.1186/s13148-022-01323-6] [Reference Citation Analysis]
3 Walz A, Van De Vyver AJ, Yu L, Birtwistle MR, Krogan NJ, Bouhaddou M. Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs. Pharmacology & Therapeutics 2022;235:108162. [DOI: 10.1016/j.pharmthera.2022.108162] [Reference Citation Analysis]
4 Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Dell'Aversana C, Bove G, Benedetti R, Montella L, Ciardiello F, Carafa V, Ambrosino C, Tucci V, Conte M, Martens JHA, Stunnenberg HG, Nebbioso A, Altucci L. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Mol Cancer 2022;21:125. [PMID: 35681235 DOI: 10.1186/s12943-022-01603-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers (Basel) 2021;13:4820. [PMID: 34638304 DOI: 10.3390/cancers13194820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
6 Schütt J, Nägler T, Schenk T, Brioli A. Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers (Basel) 2021;13:4069. [PMID: 34439223 DOI: 10.3390/cancers13164069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wan Y, Hoyle RG, Xie N, Wang W, Cai H, Zhang M, Ma Z, Xiong G, Xu X, Huang Z, Liu X, Li J, Wang C. A Super-Enhancer Driven by FOSL1 Controls miR-21-5p Expression in Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:656628. [PMID: 33937067 DOI: 10.3389/fonc.2021.656628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Shanmugam MK, Dharmarajan A, Warrier S, Bishayee A, Kumar AP, Sethi G, Ahn KS. Role of histone acetyltransferase inhibitors in cancer therapy. Adv Protein Chem Struct Biol 2021;125:149-91. [PMID: 33931138 DOI: 10.1016/bs.apcsb.2020.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
9 Batra N, De Souza C, Batra J, Raetz AG, Yu AM. The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). Int J Mol Sci 2020;21:E6412. [PMID: 32899231 DOI: 10.3390/ijms21176412] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
10 Cho Y, Kim YK. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Front Oncol 2020;10:764. [PMID: 32582535 DOI: 10.3389/fonc.2020.00764] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 20.5] [Reference Citation Analysis]
11 Ribeiro ML, Reyes-Garau D, Armengol M, Fernández-Serrano M, Roué G. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Front Genet 2019;10:986. [PMID: 31681423 DOI: 10.3389/fgene.2019.00986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kim DU, Nam J, Cha MD, Kim SW. Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway. Oncol Lett. 2019;17:3589-3598. [PMID: 30867802 DOI: 10.3892/ol.2019.9996] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
13 Vaquero-Sedas MI, Vega-Palas MÁ. Targeting Cancer through the Epigenetic Features of Telomeric Regions. Trends Cell Biol 2019;29:281-90. [PMID: 30660503 DOI: 10.1016/j.tcb.2018.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Shanmugam MK, Arfuso F, Sng JC, Bishayee A, Kumar AP, Sethi G. Epigenetic Effects of Curcumin in Cancer Prevention. Epigenetics of Cancer Prevention. Elsevier; 2019. pp. 107-28. [DOI: 10.1016/b978-0-12-812494-9.00005-6] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Rosen ED, Kaestner KH, Natarajan R, Patti ME, Sallari R, Sander M, Susztak K. Epigenetics and Epigenomics: Implications for Diabetes and Obesity. Diabetes 2018;67:1923-31. [PMID: 30237160 DOI: 10.2337/db18-0537] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 19.5] [Reference Citation Analysis]
16 Chalyk BA, Hrebeniuk KV, Gavrilenko KS, Kulik IB, Rozhenko AB, Volochnyuk DM, Liashuk OS, Grygorenko OO. Synthesis of 4-Hetarylisoxazoles from Amino Acid-Derived Halogenoximes and Push-Pull Enamines: Synthesis of 4-Hetarylisoxazoles from Amino Acid-Derived Halogenoximes and Push-Pull Enamines. Eur J Org Chem 2018;2018:5585-95. [DOI: 10.1002/ejoc.201800753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, Balkanska-Sinclair E, Yaffe MB, Floyd SR, Hammond PT. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun 2018;9:1991. [PMID: 29777137 DOI: 10.1038/s41467-018-04315-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 171] [Article Influence: 39.0] [Reference Citation Analysis]
18 Sato A, Ueno H, Fusegi M, Kaneko S, Kohno K, Virgona N, Ando A, Sekine Y, Yano T. A Succinate Ether Derivative of Tocotrienol Enhances Dickkopf-1 Gene Expression through Epigenetic Alterations in Malignant Mesothelioma Cells. Pharmacology 2018;102:26-36. [PMID: 29763912 DOI: 10.1159/000489128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Clayburgh DR, Grandis JR. Molecular Biology. Oral, Head and Neck Oncology and Reconstructive Surgery. Elsevier; 2018. pp. 79-89. [DOI: 10.1016/b978-0-323-26568-3.00003-8] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Bai ZT, Bai B, Zhu J, Di CX, Li X, Zhou WC. Epigenetic actions of environmental factors and promising drugs for cancer therapy. Oncol Lett 2018;15:2049-56. [PMID: 29434904 DOI: 10.3892/ol.2017.7597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev 2017;121:124-32. [PMID: 29079534 DOI: 10.1016/j.addr.2017.10.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
22 Rohira AD, Lonard DM. Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochemical Pharmacology 2017;140:1-7. [DOI: 10.1016/j.bcp.2017.04.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
23 Díaz-Eufracio BI, Naveja JJ, Medina-Franco JL. Protein-Protein Interaction Modulators for Epigenetic Therapies. Adv Protein Chem Struct Biol 2018;110:65-84. [PMID: 29413000 DOI: 10.1016/bs.apcsb.2017.06.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
24 Koutsogiannouli EA, Schulz WA. Histone Acetyltransferases. In: Schwab M, editor. Encyclopedia of Cancer. Berlin: Springer Berlin Heidelberg; 2017. pp. 2081-5. [DOI: 10.1007/978-3-662-46875-3_2751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Molina-Serrano D, Kirmizis A. Calorie restriction breaks an epigenetic barrier to longevity. Cell Cycle 2017;16:821-2. [PMID: 28319441 DOI: 10.1080/15384101.2017.1304745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Zhang H, Gui T, Sang Y, Yang J, Li Y, Liang G, Li T, He Q, Zha Z. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling: JQ1 S UPPRESSES C HONDROSARCOMA C ELL G ROWTH. J Cell Biochem 2017;118:2182-92. [DOI: 10.1002/jcb.25863] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
27 Ackloo S, Brown PJ, Müller S. Chemical probes targeting epigenetic proteins: Applications beyond oncology. Epigenetics 2017;12:378-400. [PMID: 28080202 DOI: 10.1080/15592294.2017.1279371] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
28 Pan D, Kather M, Willmann L, Schlimpert M, Bauer C, Lagies S, Schmidtkunz K, Eisenhardt SU, Jung M, Günther S, Kammerer B. Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7. Int J Mol Sci 2016;17:E1772. [PMID: 27783056 DOI: 10.3390/ijms17101772] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
29 Horning BD, Suciu RM, Ghadiri DA, Ulanovskaya OA, Matthews ML, Lum KM, Backus KM, Brown SJ, Rosen H, Cravatt BF. Chemical Proteomic Profiling of Human Methyltransferases. J Am Chem Soc 2016;138:13335-43. [PMID: 27689866 DOI: 10.1021/jacs.6b07830] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
30 Sun X, Liu S, Chen P, Fu D, Hou Y, Hu J, Liu Z, Jiang Y, Cao X, Cheng C, Chen X, Tao Y, Li C, Hu Y, Liu Z, Zhan Y, Mao J, Wang Q, Ma Y, Cong X, Sun R, Shi Y, Wang M, Zhang X. miR-449a inhibits colorectal cancer progression by targeting SATB2. Oncotarget 2017;8:100975-88. [PMID: 29254139 DOI: 10.18632/oncotarget.10900] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
31 Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clin Proteomics 2016;13:14. [PMID: 27382363 DOI: 10.1186/s12014-016-9115-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
32 Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11:45-53. [PMID: 27271356 DOI: 10.1007/s12072-016-9743-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
33 Vacca M, Della Ragione F, Scalabrì F, D'Esposito M. X inactivation and reactivation in X-linked diseases. Semin Cell Dev Biol 2016;56:78-87. [PMID: 26994527 DOI: 10.1016/j.semcdb.2016.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
34 McCleland ML, Mesh K, Lorenzana E, Chopra VS, Segal E, Watanabe C, Haley B, Mayba O, Yaylaoglu M, Gnad F, Firestein R. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016;126:639-652. [PMID: 26752646 DOI: 10.1172/jci83265] [Cited by in Crossref: 149] [Cited by in F6Publishing: 159] [Article Influence: 24.8] [Reference Citation Analysis]
35 Neidhart M. DNA Methylation – Introduction. DNA Methylation and Complex Human Disease. Elsevier; 2016. pp. 1-8. [DOI: 10.1016/b978-0-12-420194-1.00001-4] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Treppendahl MB, Kristensen LS, Grønbæk K. Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer. Epigenetic Biomarkers and Diagnostics 2016. [DOI: 10.1016/b978-0-12-801899-6.00005-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Aumsuwan P, Khan SI, Khan IA, Ali Z, Avula B, Walker LA, Shariat-Madar Z, Helferich WG, Katzenellenbogen BS, Dasmahapatra AK. The anticancer potential of steroidal saponin, dioscin, isolated from wild yam (Dioscorea villosa) root extract in invasive human breast cancer cell line MDA-MB-231 in vitro. Arch Biochem Biophys 2016;591:98-110. [PMID: 26682631 DOI: 10.1016/j.abb.2015.12.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
38 Miousse IR, Currie R, Datta K, Ellinger-Ziegelbauer H, French JE, Harrill AH, Koturbash I, Lawton M, Mann D, Meehan RR, Moggs JG, O'Lone R, Rasoulpour RJ, Pera RA, Thompson K. Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute. Toxicology 2015;335:11-9. [PMID: 26134581 DOI: 10.1016/j.tox.2015.06.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
39 Katoh M. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. Expert Rev Proteomics. 2015;12:317-328. [PMID: 25835095 DOI: 10.1586/14789450.2015.1033409] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
40 D'Amato L, Dell'Aversana C, Conte M, Ciotta A, Scisciola L, Carissimo A, Nebbioso A, Altucci L. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. Epigenetics 2015;10:6-18. [PMID: 25494542 DOI: 10.4161/15592294.2014.988035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
41 Kyburz D, Karouzakis E, Ospelt C. Epigenetic changes: The missing link. Best Practice & Research Clinical Rheumatology 2014;28:577-87. [DOI: 10.1016/j.berh.2014.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
42 Koutsogiannouli EA, Schulz WA. Histone Acetyltransferases. Encyclopedia of Cancer 2014. [DOI: 10.1007/978-3-642-27841-9_2751-2] [Reference Citation Analysis]